Study to Evaluate the Immunogenicity and Safety of a Heterologous Vaccine Regimen Against Ebola (EBOVAC3DRC)
Open-label Phase 2 Study to Evaluate the Immunogenicity and Safety of a Prophylactic Vaccination of Health Care Providers by Administration of a Heterologous Vaccine Regimen Against Ebola in the Democratic Republic of the Congo
Sponsor: Ace Africa
A PHASE2 clinical study on Ebola Virus Disease, this trial is completed. The trial is conducted by Ace Africa and has accumulated 10 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Feb 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Oct 2022 — Feb 2023 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
▶ Show 5 earlier versions
-
Oct 2021 — Oct 2022 [monthly]
Active Not Recruiting PHASE2
-
Jan 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE2
-
Oct 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Feb 2020 — Oct 2020 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jan 2020 — Feb 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Dec 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ace Africa
- Coalition for Epidemic Preparedness Innovations
- Innovative Medicines Initiative
- Johnson & Johnson
- Universiteit Antwerpen
- University of Kinshasa
For direct contact, visit the study record on ClinicalTrials.gov .